Ocular Therapeutix (OCUL) Interest & Investment Income (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Interest & Investment Income of $5.4 million for Q2 2026, up 57.71% year-over-year from $3.5 million in Q2 2025, and down 9.93% on a QoQ basis from $6.0 million in Q1 2026.
Powered by 
Analysis
Ocular Therapeutix (OCUL) Interest & Investment Income (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Interest & Investment Income for 14 years, with the latest figure at $5.4 million in Q2 2026.
- Interest & Investment Income for Q2 2026 came in at $5.4 million, up 57.71% year-over-year; the trailing twelve-month figure through Jun 2026 was $22.6 million (up 28.21% YoY), and the FY2025 annual result was $18.4 million, down 9.5% from the prior year.
- Interest & Investment Income fell to $5.4 million in Q2 2026, from $6.0 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $7.3 million in Q4 2025 and troughed at $18000.0 in Q1 2022.
- A 5-year average of $3.1 million and a median of $3.6 million in 2025 frame the typical range for Interest & Investment Income.
- The widest annual swing landed in 2022, when Interest & Investment Income jumped 6950.0%; it then slumped 42.76% in 2025.
- A 5-year view of Interest & Investment Income shows it stood at $423000.0 in 2022, then soared by 244.92% to $1.5 million in 2023, then surged by 220.15% to $4.7 million in 2024, then soared by 57.2% to $7.3 million in 2025, then declined by 25.79% to $5.4 million in 2026.
- Per Business Quant data, the three most recent Interest & Investment Income figures were $5.4 million in Q2 2026, $6.0 million in Q1 2026, and $7.3 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Ocular Therapeutix | 2.41 Bn | 2.41 Bn | 11.46 Mn | 5.45 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.45 Mn |
| Mar 31, 2026 | 6.05 Mn |
| Dec 31, 2025 | 7.34 Mn |
| Sep 30, 2025 | 3.73 Mn |
| Jun 30, 2025 | 3.46 Mn |
| Mar 31, 2025 | 3.83 Mn |
| Dec 31, 2024 | 4.67 Mn |
| Sep 30, 2024 | 5.65 Mn |
| Jun 30, 2024 | 6.04 Mn |
| Mar 31, 2024 | 3.92 Mn |
| Dec 31, 2023 | 1.46 Mn |
| Sep 30, 2023 | 1.21 Mn |
| Jun 30, 2023 | 748,000.00 |
| Mar 31, 2023 | 563,000.00 |
| Dec 31, 2022 | 423,000.00 |
| Sep 30, 2022 | 285,000.00 |
| Jun 30, 2022 | 73,000.00 |
| Mar 31, 2022 | 18,000.00 |
| Dec 31, 2021 | 6,000.00 |
| Sep 30, 2021 | 7,000.00 |